Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Published byJohnathan Casey Modified over 5 years ago

Similar presentations

Presentation on theme: "Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,"— Presentation transcript:

1 Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer 
Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin, MD, Benjamin Besse, MD, PhD  Journal of Thoracic Oncology  Volume 13, Issue 1, Pages (January 2018) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Rearranged during transfection proto-oncogene gene (RET) receptor (A) and KIF5B-RET fusion protein (B) activations, with associated triggered downstream pathways. TM, transmembrane domain; E, exon; TK, tyrosine kinase; GFLs, GDNF family of ligands; GFRα, GDNF family receptor α; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; JAK, Janus kinase; STAT, signal transducer and activator of transcription; KIF5B, kinesin family member 5B. (Modified with permission from Gainor and Shaw.30) Journal of Thoracic Oncology  , 27-45DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 The most frequent rearranged during transfection proto-oncogene gene (RET) rearrangements: kinesin family member 5B gene (KIF5B)-RET (seven variants), coiled-coil domain containing 6 (CCDC6)-RET, nuclear receptor coactivator 4 (NCOA4)-RET, and tripartite motif containing 33 (TRIM33)-RET. E, exon; TM, transmembrane domain. (Modified with permission from Gainor and Shaw.30) Journal of Thoracic Oncology  , 27-45DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Pericentric inversion chromosome 10 (kinesin family member 5B gene [KIF5B]– rearranged during transfection proto-oncogene gene [RET]) in lung adenocarcinoma. (Modified with permission from Kohno et al.54) Journal of Thoracic Oncology  , 27-45DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Rearranged during transfection proto-oncogene gene (RET) rearrangements by fluorescence in situ hybridization (FISH) analysis (break-apart assay; ZytoLight SPEC RET dual Color Break Apart Probe, Zytovision, CliniSciences, Nanterre, France) in two patients with lung adenocarcinoma. (A) One or two native alleles (N) and a rearranged allele (R) are present. The green spots (probe 3′ RET) and the red spots (probe 5′ RET) are split, revealing a rearrangement of the RET gene. The short distance between the two parts of the probe suggests a rearrangement with kinesin family member 5B gene (KIF5B) on the chromosome 10p. (B) A different pattern of RET rearrangement, with one or two native alleles (N), loss of the 5′ end (red signal) of the RET gene, and concomitant duplication of the derivative chromosome (R). Journal of Thoracic Oncology  , 27-45DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

6 Figure 5 Overall response rates of multikinase inhibitors in patients with rearranged during transfection proto-oncogene gene (RET)-rearranged NSCLC, by study. ∗, Phase I; °, phase II, and ϕ, retrospective. Journal of Thoracic Oncology  , 27-45DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

7 Figure 6 Overall response rates according to rearranged during transfection proto-oncogene gene (RET) fusion variants (kinesin family member 5B gene [KIF5B]-RET versus non–KIF5B-RET) in patients with NSCLC, by study. Journal of Thoracic Oncology  , 27-45DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

8 Figure 7 Escape mechanisms to rearranged during transfection proto-oncogene (RET) inhibition and potential treatment strategies to overcome resistance. RTK, receptor tyrosine kinase; MET, MET proto-oncogene, receptor tyrosine kinase; PI3K, phosphoinositide 3-kinase; AKT2, AKT/serine threonine kinase 2; MAPK, mitogen-activated protein kinase; TKI, tyrosine kinase inhibitor; mTOR, mechanistic target of rapamycin; MDM2, MDM2 proto-oncogene; APC, WNT signaling pathway regulator; mut, mutation. Journal of Thoracic Oncology  , 27-45DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,"

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Naomi Fujioka, MD, Christopher A. French, MD, Michael J
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Rafal Dziadziuszko, MD, PhD, Anh T

Rafal Dziadziuszko, MD, PhD, Anh T
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Recent Advances in Targeting ROS1 in Lung Cancer

Recent Advances in Targeting ROS1 in Lung Cancer
cMET Exon 14 Skipping: From the Structure to the Clinic

cMET Exon 14 Skipping: From the Structure to the Clinic
Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,
Figure 1 A schematic representation of the HER2 signalling pathway

Figure 1 A schematic representation of the HER2 signalling pathway
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Similar presentations

Ads by Google